Nyse rcus.

According to the issued ratings of 8 analysts in the last year, the consensus rating for Arcus Biosciences stock is Moderate Buy based on the current 1 hold rating and 7 buy ratings for RCUS. The average twelve-month price prediction for Arcus Biosciences is $43.13 with a high price target of $70.00 and a low price target of $23.00.Citing the data from interim analysis for ARC-7 trial expected in Q2 2021, BTIG analysts led by Thomas Shrader have rated Arcus Biosciences (NYSE:RCUS) buy with the price target of $57.00 per ...Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions. [Operator instructions] This call is being recorded and will be available on the investors section of the ARCUS …However, on September 5, Bank of America Securities reiterated a Hold rating on Arcus Biosciences (NYSE: RCUS). See today’s best-performing stocks on TipRanks >> RCUS market cap is currently $1 ...

FOSTER CITY, Calif. & HAYWARD, Calif., November 28, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis ...Arcus Biosciences, Inc. , an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of...

Dec 4, 2023 · The RCUS shares have gain 14.30% over the last week, with a monthly amount glided 1.58%, and seem At the time of writing, Arcus Biosciences Inc [RCUS] stock is trading at $16.07, up 6.71%. It is a good measure of the stock's recent performance to check whether the stock's short-term value is rising or falling.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor ...Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. NYSE: Arcus Biosciences Inc (RCUS) = 14.62 USD. Provided by Alpha Vantage. Arcus Biosciences Inc stock (RCUS) in USD. 1 RCUS = 14.62 USD. 1 month. 6 months. 1 year. …

Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...

Experience · Spotify officially begins trading on the NYSE T 26, Stock Market Investing, Nasdaq, ... (NYSE: RCUS). NYSE · Experience an IPO · Milestones · Ceo.Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Dimitry S.A. Nuyten, M.D., Ph.D has been appointed chief medical officer (CMO) effective August 1, 2022.HAYWARD, Calif., August 07, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...NYSE RCUS, also known as Renovacor, is a biotechnology company listed on the New York Stock Exchange (NYSE) under the ticker symbol RCUS. Renovacor focuses on developing gene therapies for cardiovascular diseases, aiming to provide effective treatments for patients suffering from debilitating conditions such as dilated …NYSE:RCUS - Analysts future estimates and past financials data (USD Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts; 12/31/2025: 137-330-327HAYWARD, Calif. - July 19, 2021 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences as senior …NYSE:RCUS - Analysts future estimates and past financials data (USD Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts; 12/31/2025: 137-330-327

You might want to add that Arcus CEO Terry Rosen bought just over 71,000 shares of RCUS in the open market, investing just over $1 million between Aug. 10th and Aug. 28th 2018. If that isn't a ...HAYWARD, Calif., November 27, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated …Aug. 22, 2023, 09:45 PM. In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Arcus Biosciences ( RCUS – Research Report ), with a price target of $51 ...Best Mid-Cap Companies (2021) Dropped off in 2022. #27. Best Small Cap Companies (2021) Dropped off in 2022. Arcus Biosciences (RCUS) Stock Price Performance. Arcus Biosciences (RCUS) Stock Key ... Roche drives rival anti-TIGIT developers higher after cancer drug data. May 26, 2023 11:19 AM ET Roche Holding AG (RHHBY), ITOS, CGEN, RCUS RHHBF By: Dulan Lokuwithana, SA News Editor. Hailshadow ...What's going on at Arcus Biosciences (NYSE:RCUS)? Read today's RCUS news from trusted media outlets at MarketBeat.Dec 1, 2023 · Source. Headline. From laggards to leaders: Small caps on the rise (RCUS) marketbeat.com - November 27 at 8:45 AM. Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $43.13. americanbankingnews.com - November 26 at 2:30 AM. Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey. seekingalpha.com - November 20 at 5:46 PM.

Nov 23, 2023 · Arcus Biosciences Stock Performance. NYSE RCUS opened at $13.87 on Thursday. Arcus Biosciences has a one year low of $12.95 and a one year high of $36.13. The firm’s fifty day moving average is $16.47 and its two-hundred day moving average is $18.74. The firm has a market cap of $1.04 billion, a PE ratio of -3.47 and a beta of 0.76.

Whatever the trade. Get a brief overview of Arcus Biosciences, Inc. financials with all the important numbers. View the latest RCUS income statement, balance sheet, and financial ratios.Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s share price fell 3.7% during mid-day trading on Friday . The stock traded as low as $14.45 and last traded at $14.50. 19,641 shares were ...Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. Discover historical prices for RCUS stock on Yahoo Finance. View daily, weekly or monthly format back to when Arcus Biosciences, Inc. stock was issued. ... NYSE - NYSE Delayed Price. Currency in ... Gainers: MoSys (NASDAQ:MOSY) +100%.Liberty TripAdvisor (NASDAQ:LTRPB) +87%.Arcus Biosciences (NYSE:RCUS) +76%.Edison Nation (NASDAQ:EDNT) +70%.Taronis...NYSE Arca Telecommunications Index Today: Get all information on the NYSE Arca Telecommunications Index Index including historical chart, news and constituents. Indices Commodities Currencies Stocks

RCUSNYSE See on Supercharts Overview News Ideas Financials Technicals Forecast RCUS chart Today 3.13% 5 days 8.30% 1 month −11.75% 6 months −18.14% Year to …

ARCUS BIOSCIENCES (NYSE: RCUS.US) | Ticker Rank: 17965 (+70) | ☆ 3. 2023101222001120231013020000. After Hours (half-spread): 13 paź, 2:00 16.9250 +1.1050 (+ ...

May 17, 2023 · HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ... HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...NYSE:RCUS - Analysts future estimates and past financials data (USD Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts; 12/31/2025: 137-330-327Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BeiGene (BGNE – Research Report), Arcus Biosc... Companies in the Healthcare sector have received a lot of coverage today as analysts weigh i...A high-level overview of Arcus Biosciences, Inc. (RCUS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.I last covered Arcus Biosciences (NYSE:RCUS) for Seeking Alpha back in March 2020, giving the company' stock a "BUY" rating - more than 3 years later, Arcus stock has reached a value of $20 at the ...Nov 24, 2023 · A high-level overview of Arcus Biosciences, Inc. (RCUS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Citing the data from interim analysis for ARC-7 trial expected in Q2 2021, BTIG analysts led by Thomas Shrader have rated Arcus Biosciences (NYSE:RCUS) buy with the price target of $57.00 per ...HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...HAYWARD, Calif., November 27, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination...

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions. [Operator instructions] This call is being recorded and will be available on the investors section of the ARCUS …Arcus Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RCUS updated stock price target summary. NYSE - NYSE Delayed Price. Currency in USD Follow 2W 10W 9M 14.06 0.00 (0.00%) At close: 04:00PM EST 13.56 -0.50 (-3.56%) Pre-Market: 07:01AM EST 1d 5d 1m 6m YTD …FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor ...Instagram:https://instagram. worst months for the stock marketoptions volume trackermedicaid cover braces for adultsdentalplans.com cigna Arcus Biosciences ( NYSE:RCUS – Get Free Report) last announced its earnings results on Tuesday, November 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating ... what stocks to buy tomorrowwhen can you pre order iphone 15 pro max HAYWARD, Calif., October 17, 2023--Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society ...Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common ... general electric engines Nov 27, 2023 · NYSE RCUS, also known as Renovacor, is a biotechnology company listed on the New York Stock Exchange (NYSE) under the ticker symbol RCUS. Renovacor focuses on developing gene therapies for cardiovascular diseases, aiming to provide effective treatments for patients suffering from debilitating conditions such as dilated cardiomyopathy (DCM). 1. HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Arcus Biosciences, Inc. (NYSE:RCUS) is the most popular stock in this table. On the other hand Washington Trust Bancorp (NASDAQ: WASH ) is the least popular one with only 7 bullish hedge fund ...